SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster

In this study we assessed serum SARS-CoV-2-neutralising titres in 70 longitudinal samples from 18 immunocompetent individuals after multiple mRNA vaccine doses to track antibody dynamics over time. A small increase in NAb titres was seen against BA.5 and XBB.1.5 approximately 1 month after the B1 bo...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2023-11, Vol.402 (10415), p.1827-1828
Main Authors: Wang, Qian, Bowen, Anthony, Ho, Jerren, Zhang, Richard M, Valdez, Riccardo, Stoneman, Emily, Gordon, Aubree, Liu, Lihong, Ho, David D
Format: Article
Language:English
Subjects:
Antibodies
COVID-19 vaccines
Immunology
Infectious diseases
mRNA
mRNA vaccines
Severe acute respiratory syndrome coronavirus 2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study we assessed serum SARS-CoV-2-neutralising titres in 70 longitudinal samples from 18 immunocompetent individuals after multiple mRNA vaccine doses to track antibody dynamics over time. A small increase in NAb titres was seen against BA.5 and XBB.1.5 approximately 1 month after the B1 booster, but this difference did not persist over time, consistent with previous findings.3,4 When adjusting for multiple comparisons, no groups were significantly different (appendix p 4). AB was supported in part by T32AI100852, Columbia Integrated Training Program in Infectious Disease Research.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(23)02278-X